Hui-Di Lan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hui-Di Lan has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Jian-Ping Liu
Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, China
3 shared publications - Mei Han
Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
2 shared publications - Min Fang
Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
2 shared publications - Nicola Robinson
Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China; Institute of Health and Social Care, London South Bank University, London SE1 0AA, UK
2 shared publications - Ruo-Xiang Zheng
Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
2 shared publications - Xiao-Yang Hu
Primary Care Research Centre, School of Primary Care, Population Sciences & Medical Education, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 18 February 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-12
Traditional Chinese Medicine for HIV-Associated Acute Herpes Zoster: A Systematic Review and Meta-Analysis of Randomized Trials
Background. Herpes zoster (HZ) is a common infection in individuals with acquired immunodeficiency syndrome (AIDS) patients. Traditional Chinese medicine (TCM) has been used widely in clinical practice for HZ, which remains not supportive of evidence. This review aimed to evaluate the effectiveness and safety of TCM in treating HIV-associated HZ. Methods. Nine electronic databases were searched for randomized controlled trials (RCTs) testing TCM in treating HIV-associated HZ. Data were extracted on citations, interventions, and outcomes, by two authors independently. For the quality evaluation, Cochrane risk-of-bias tool 2.0 was used. Meta-analyses were performed by Revman5.3 software. Effect estimation presented as risk ratio (RR) for dichotomous data and mean difference (MD) for continuous data with their 95 confidence interval (CI). Results. Twelve RCTs (n=644) were included; the majority of them had a high or unclear risk of bias. Meta-analysis showed that pain intensity (VAS 05) in the Chinese herbal medicine (CHM) group was lower than it in the drugs group (MD=0.87, 95 CI [1.69, 0.04], two trials, n=93). Duration of herpes-related pain (days) of patients in the combination group was shorter than those in the drugs group (MD=9.19, 95 CI [16.73, 1.65], n=144). The incidence of postherpetic neuralgia (PHN) in the combination group was lower than in the drugs group (RR=0.49, 95 CI [0.25, 0.99], n=202). As for cure rate (complete absence of pain and herpes), two trials showed that CHM was better than drugs (RR=1.58, 95 CI [1.13, 2.22], n=93), five trials showed combination treatment was better than drugs (RR=1.40, 95 CI [1.08, 1.82], n=224). The cure rate in the acupuncture group was more than that in the drugs group (RR=1.99, 95 CI [1.18, 3.36], n=120). Four trials reported adverse effects and found no serious adverse events occurred. Conclusion. CHM and acupuncture demonstrate more benefits than drugs in pain relief, cure rate improvement, and incidence reduction of PHN. However, given the data limitation and TCM therapies diversity, the conclusions need to be verified in future trials.
- 18 February 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-12
Open AccessTraditional Chinese Medicine for HIV-Associated Acute Herpes Zoster: A Systematic Review and Meta-Analysis of Randomized Trials
Background. Herpes zoster (HZ) is a common infection in individuals with acquired immunodeficiency syndrome (AIDS) patients. Traditional Chinese medicine (TCM) has been used widely in clinical practice for HZ, which remains not supportive of evidence. This review aimed to evaluate the effectiveness and safety of TCM in treating HIV-associated HZ. Methods. Nine electronic databases were searched for randomized controlled trials (RCTs) testing TCM in treating HIV-associated HZ. Data were extracted on citations, interventions, and outcomes, by two authors independently. For the quality evaluation, Cochrane risk-of-bias tool 2.0 was used. Meta-analyses were performed by Revman5.3 software. Effect estimation presented as risk ratio (RR) for dichotomous data and mean difference (MD) for continuous data with their 95 confidence interval (CI). Results. Twelve RCTs (n=644) were included; the majority of them had a high or unclear risk of bias. Meta-analysis showed that pain intensity (VAS 05) in the Chinese herbal medicine (CHM) group was lower than it in the drugs group (MD=0.87, 95 CI [1.69, 0.04], two trials, n=93). Duration of herpes-related pain (days) of patients in the combination group was shorter than those in the drugs group (MD=9.19, 95 CI [16.73, 1.65], n=144). The incidence of postherpetic neuralgia (PHN) in the combination group was lower than in the drugs group (RR=0.49, 95 CI [0.25, 0.99], n=202). As for cure rate (complete absence of pain and herpes), two trials showed that CHM was better than drugs (RR=1.58, 95 CI [1.13, 2.22], n=93), five trials showed combination treatment was better than drugs (RR=1.40, 95 CI [1.08, 1.82], n=224). The cure rate in the acupuncture group was more than that in the drugs group (RR=1.99, 95 CI [1.18, 3.36], n=120). Four trials reported adverse effects and found no serious adverse events occurred. Conclusion. CHM and acupuncture demonstrate more benefits than drugs in pain relief, cure rate improvement, and incidence reduction of PHN. However, given the data limitation and TCM therapies diversity, the conclusions need to be verified in future trials.
- Open Access
- 19 October 2021
- Published by Elsevier in Integrative Medicine Research
- Vol. 10 (Suppl) , 100798
Traditional Chinese medicine for COVID-19 pandemic and emerging challenges: An online cross-sectional survey in China
- 19 October 2021
- Published by Elsevier in Integrative Medicine Research
- Vol. 10 (Suppl) , 100798
Open AccessTraditional Chinese medicine for COVID-19 pandemic and emerging challenges: An online cross-sectional survey in China
- Open Access
- 1 August 2021
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 60, 102744
Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials
- 1 August 2021
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 60, 102744
Open AccessTherapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials